<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365301">
  <stage>Registered</stage>
  <submitdate>13/11/2013</submitdate>
  <approvaldate>18/11/2013</approvaldate>
  <actrnumber>ACTRN12613001258741</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in the provinces of  Zivie/Atlantic, Kouande/Atacora and Zakpota /Zou in the Republic of Benin</studytitle>
    <scientifictitle>Therapeutic efficacy and safety study of fixed combination of artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria in the provinces of  Zivie/Atlantic, Kouande/Atacora and Zakpota /Zou in the Republic of Benin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncomplicated falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a an open label single arm surveillance study to confirm the efficacy and safety of the first-line antimalarial treatment, artemether-lumefantrine, for the treatment of uncomplicated falciparum malaria in children aged between 6 months a 12 years.  All eligible patients will be enrolled on day 0 and received artemether-lumefantrine as fixed-combination tablet (20 mg artemether and 120 mg lumefantrine) twice daily for 3 consecutive days.  The number of tablets to be administered for each dose ( morning and evening) is based on body weight according to standard treatment (5-14 kg, 1 tb; 15-24 kg, 2 tb; 25-34 kg, 3 tb; over 35 kg 4 tb).  Each dose will be administered under the supervision of a qualified study staff member.  Clinical and parasitological examinations will be conducted at each of the scheduled follow-up visit on days 1,2,3,7,14,21, and 28 or any other day if symptoms re-occurred.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with adequate clinical and parasitological response adjusted by PCR (polymerase chain reaction)</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and nature of adverse events.  Possible adverse events are those known to occur with antimalarials and include, headache, body ache, nausea, vomiting, abdominal discomfort, liver enzyme elelevation, and dizziness</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematocrit</outcome>
      <timepoint>Baseline and Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In vitro susceptibility testing of Plasmodium isolates to artemether-lumefantrine</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age between 6 months and 12 years
Minimum body weight of 5kg
Mono-infection with plasmodium falciparum confirmed by microscopy
Parasitemia between 1000-200000 asexual forms parasites per microliter
Axillary temperature equal or greater than 37.5 degrees Celsius or history of fever in the past 24 hours
Able to swallow oral medication
Capable and willing to follow protocol requirement, including schedule of assessments
Written consent from parent/guardian

</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Presence of signs in children aged under 5 years, or signs of severe falciparum malaria according to WHO definition
Mixed or mono infection with another Plasmodium species detected by microscopy
Presence of severe malnutrition (defined as a child whose growth standard is below minus 3z score, has symmetrical oedema involving at least the feet, or has mid-upper arm circumference less than 110 mm
Presence of febrile conditions due to diseases other than malaria (measles, acute lower respiratory tract infection, severe diarrhea with dehydration), or other known underlying chronic diseases (cardiac, renal and hepatic diseases, HIV/AIDS)
Regular medications, which may interfere with the antimalarial pharmacokinetics
History of hypersensitivity reaction or contraindications to any of the medicine(s) being tested or used as alternative treatments</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>22/11/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/01/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Benin</country>
      <state>Zinvie/Altlantic</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Benin</country>
      <state>Kouande/Atacora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Benin</country>
      <state>Zakpota/Zou</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministere de la Sante Benin</primarysponsorname>
    <primarysponsoraddress>01 BP882
Cotonou</primarysponsoraddress>
    <primarysponsorcountry>Benin</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministere de la Sante Benin
Programme National de Lutte contre le Paludisme (PNLP)
</fundingname>
      <fundingaddress>01 BP882
Cotonou</fundingaddress>
      <fundingcountry>Benin</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>20 Avenue Appia
CH 1211 Geneva 27</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open label prospective surveillance study to confirm the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciaprum malaria in children from 6 months to 12 years of age  in three provinces of Benin. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>World Health Organisation Ethics Review Committee</ethicname>
      <ethicaddress>20 Avenue Appia
CH1211 Geneva 27</ethicaddress>
      <ethicapprovaldate>8/11/2013</ethicapprovaldate>
      <hrec>RPC597</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Yves Eric Donan Denon</name>
      <address>Programme National de Lutte contre le Paludisme (PNLP)
01 BP 6974
Cotonou</address>
      <phone>+229 2133930</phone>
      <fax />
      <email>denric2000@yahoo.fr</email>
      <country>Benin</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yves Eric Donan Denon</name>
      <address>Programme National de lutte contre le Paludisme (PNLP)
01 BP 6974
Cotonou</address>
      <phone>+229 2133930</phone>
      <fax />
      <email>denric2000@yahoo.fr</email>
      <country>Benin</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yves Eric Donan Denon</name>
      <address>Programme National de lutte contre le Paludisme (PNLP)
01 BP 6974
Cotonou</address>
      <phone>+229 2133930</phone>
      <fax />
      <email>denric2000@yahoo.fr</email>
      <country>Benin</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Pascal Ringwald</name>
      <address>WHO
20 avenue Appia
CH1211 Geneva 27</address>
      <phone>+41 227913469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>